Valuation — not yet established
No valuation for Spine BioPharma is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($58.8M) and the funding record below are the closest available signals.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
See the evidence behind this price
- ·Post-money valuations for all 8 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Spine BioPharma
Create free account
No card required
Funding history
8 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| May 2026 | Seed Round | $385K | ▮ | ▮ |
| Sep 2024 | Early Stage VC | $13.5M | ▮ | ▮ |
| Oct 2023 | Seed Round | $2.4M | ▮ | ▮ |
| Aug 2023 | Seed Round | $1.9M | ▮ | ▮ |
| Feb 2023 | Debt | $13.0M | ▮ | ▮ |
| Mar 2022 | Early Stage VC | $13.0M | ▮ | ▮ |
| + 2 earlier rounds · a free account shows the full history | ||||
How Spine BioPharma's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Spine BioPharma, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- How much has Spine BioPharma raised?
- Spine BioPharma has raised $58.8M in total funding across 8 recorded rounds.
- When did Spine BioPharma last raise?
- Spine BioPharma last raised in May 2026 (Seed Round), raising $385K.